STOCKS TELEGRAPH

Author: ST Staff

  • What Drove CGXEF Stock Up 32% Last Session?

    What Drove CGXEF Stock Up 32% Last Session?

    After seeing a rise of 31.93%, CGX Energy Inc (OTCPk: CGXEF) closed at $2.19, taking its market cap to $629.82M. CGXEF stock traded 1.91M shares, a volume which was greater than its average daily volume of 106.54K. Additionally, CGXEF has traded in an intraday range of $1.65 to $2.20. There are 287.59M shares outstanding in the pink sheets CGXEF, compared to 74.78M shares float. Because CGXEF stock increased when no current news was available, there are some reasons to believe that recent developments will enable us to gain additional insight into CGXEF.

    How has CGXEF been recently?

    Canada’s CGX has four exploration licenses in the Guyana-Suriname basin. Located in the frontier basin of South America, the basin features both proven hydrocarbon systems and deep water plays that can be drilled up to 200 feet underwater. U.S. Geological Survey (USGS) has identified the Guyana Suriname basin as the world’s second most promising unexplored oil basin, with recoverable oil reserves and gas reserves of over 13.6 billion barrels and 39 trillion cubic feet of reserves, respectively. CGXEF is well-positioned to capitalize on Guyana’s Atlantic Basin, with more than 10 prospects and leads, and an independent P50 resource estimate of 3 billion barrels of potential.

    It was announced last month that CGX Energy had completed its loan agreement with Frontera Energy Corporation (“Frontera”).

    • The CGXEF loan agreement stems from the recent US$19 million loan announcement made on April 16, 2021.
    • The loan allows CGXEF to continue financing its share of the costs for the Demerara, Berbice, Corentyne blocks, and to facilitate other budgeted expenses.
    • Related party transactions between CGXEF and Frontera are eligible for Minority Security Holder Protection under Multilateral Instrument 61-101.
    • Additional Information
    • Frontera has the option to acquire a maximum of 26,685,393 Common Shares upon the conversion of the loan.
    • On a partially diluted basis, Frontera would have 76.07% of the issued and outstanding Common Shares of CGXEF.
    • There is a statutory hold period expiring on September 29, 2021 for Common Shares to be issued in connection with the conversion of the Loan.
    • The TSX Venture Exchange must accept CGXEF’s loan before it can be finalized.

    Partnership for JV:

    Both CGX Energy (CGXEF) and Frontera are also in a joint venture to explore the Corentyne block offshore Guyana for petroleum. Maersk Drilling Holdings Singapore Pte Ltd. (Maersk) has recently been engaged by CGX Resources Inc. to provide a semi-submersible drilling unit and associated services to drill the Joint Venture’s Kawa-1 well.

  • On What Basis Did OMID Stock Drop 18%?

    On What Basis Did OMID Stock Drop 18%?

    The stock of OMID Holdings, Inc. (OTCPINK: OMID) closed down -18.52 percent on Friday at $0.0880 and has been trading between $0.0860 and $0.1080 in day’s trade. The OMID stock increased over 32.33% in the last month, with average volume over 408.33K shares.

    A three-month performance analysis shows OMID stock falling over -16.19% while its average volume was 330.68K. OMID stock experienced a 723.15% gain in the last 12 months, reaching a high of $0.1990 with a market cap of $8.47M. OMID stock plummeted as it announced reduction in its common shares.

    OMID reduced its shares by how much?

    Its FDA-registered clean room facility in Phillipsburg, NJ, is where OMID develops and manufactures various health and wellness products. In addition to cannabis extracts and other herbal ingredients, OMID offers a diverse portfolio of product categories. In all of its finished goods, OMID provides quality, integrity, and significant value with noticeable benefits for consumers.

    In response to shareholder requests, OMID on Thursday completed the process of reducing the outstanding number of common shares. A total of One-Hundred-Four Million (164,000,000) OMID common shares has been removed from the outstanding stock as previously disclosed in March. The board of OMID intended to clearly show its support for the company’s long-term potential with this corporate action, the second share reduction of the year..

    Purchase of Champ Life by OMID:

    OMID recently completed the acquisition of Champ Life, a new health and wellness brand.

    • OMID’s issued and outstanding share structure has not been altered as a result of this acquisition.
    • The Seller will receive 5% of net revenues from sales of Champ Life as part of the transaction, supporting various activities relating to launching and growing the business.
    • OMID management may eliminate this royalty if Champ Life achieves over $1,000,000 in net revenues in any calendar year following the sale of the brand.
    • By adding nootropics such as herb and mushroom adaptogens to its product line, OMID will broaden its market reach and enhance product benefits.
    • Management has cancelled personal shares in order to balance the shares issued in this acquisition in keeping with its commitment to shareholders.

    How OMID will go through these developments?

    The reduction in its common stock represents OMID’s ongoing commitment to make sure all shareholders remain loyal to its business. Moreover, Champ Life is OMID’s next step while the company aims to expand into the athletic and biohacking market, as well as continuing to focus on cannabis.

  • What Is Driving The Anavex (AVXL) Stock Higher In Premarket Trades?

    What Is Driving The Anavex (AVXL) Stock Higher In Premarket Trades?

    In pre-market trading hours on Monday, Anavex Life Sciences Corp. (AVXL) rose 27.96% to $31.67. At the end of the last trading session, AVXL stock price slipped -0.76% to $24.75. AVXL stock price ranged between $24.02 and $25.30.

    AVXL traded 2.11 million shares, which was lower than its average daily volume of 3.5 million shares over the past 100 days. In the last five days, AVXL stock has gained 11.79%, while in the last month, it gained 104.38%. AVXL stock is rising after a clinical trial announced improved results.

    Which trial did AVXL conduct?

    Anavex is a public company that develops differentiated therapeutics to treat neurological disorders and neurodegenerative diseases. This includes Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other diseases related to the central nervous system (CNS), pain and cancer. As a result of a successful Phase 2, a clinical trial for Alzheimer’s disease, ANAVEX2-73 is the lead drug candidate by AVXL.

    A phase 2 proof-of-concept study of AVXL’s lead drug in Parkinson’s disease dementia was completed recently, as well as a phase 2 study in adults with Rett syndrome. AVXL believes that the easily accessible predictive biomarker combined with the observed efficacy is a consistent explanation of the efficacy in this second largest CNS indication with unmet medical need.

    In a report released today, Anavex reported that the predictive biomarkers of response that correlate significantly with clinical outcomes in clinical efficacy endpoints in primary and secondary endpoints.

    • Results came from the proof-of-concept randomized, double-blind, placebo-controlled Phase 2 trial in which 132 Parkinson’s patients were assigned equally to either 30 mg, 50 mg of ANAVEX 2-73 or a placebo.
    • In ANAVEX 2-73, the sigma-1 receptor (SIGMAR1) is activated.
    • SIGMAR1 activation resulted in the restoration of complete housekeeping functions within the brain and is pivotal in maintaining neuronal homeostasis and enhancing neuroplasticity.
    • A recent independent study by AVXL provides more evidence that SIGMAR1 activation is beneficial in compensating for chronic CNS diseases.
    • As a result of the easily accessible predictive biomarker coupled with the observed efficacy, AVXL believes that this is the second largest CNS indication where there is unmet medical need.

    Anavex announced last week that the previously announced registered direct offering to Deep Track Capital has closed. At $21.00 per share, AVXL plans to issue and sell 2,380,953 shares of its common stock. For AVXL’s offering, HC Wainwright & Co. served as the listing agent.

    What AVXL received?

    After deducting placement agent fees and other expenses from the proceeds, AVXL received approximately $50 million from the offering. Anavex (AVXL) plans to use sales proceeds from the offering for the advancement of its pipeline, for continuing operations, and general corporate purposes.

  • Intellia Therapeutics Inc. (NTLA) stock jumped in the premarket trading session; find out why

    Intellia Therapeutics Inc. (NTLA) stock jumped in the premarket trading session; find out why

    In the premarket trading session, Intellia Therapeutics Inc. (NTLA) stock has had its shares advance by 57.72% to trade at the price of $140.10 at the last check. NTLA stock has closed its previous sessing with a gain on Monday for 2.29% at $88.83. The NTLA stock traded a volume of 2.61 million shares. In the past year up to date, the NTLA stock have risen by 313.36% and in the past week, they jumped up by 17.00%. In the past three and six months, the stock has surged by 37.23% and added 40.22%. Furthermore, the company is currently valued in the market at $5.92 billion and has 67.18 million outstanding shares.

    Dwelling deeper into the operations of Intellia Therapeutics Inc.

    Intellia Therapeutics Inc. is a biotechnology company that specifically focuses on the research, development and application of genome editing. The company focuses on the utilization of different kinds of for the analysis and testing of gene editing and studying. These gene editing applications will then be used in the development of therapeutics. NTLA stock uses tools like Clustered, Regularly Interspaced Short Palindromic Repeats which is shortly known as CRISPR which is associated with the Cas9 system. One of the recent programs highlighted in the company are the Vivo programs which include the trial for the treatment of thansthyretin amyloidosis known as NTLA-2001. The program is in phase 1 clinical trial and the NTLA-2002 which is being developed from the treatment of hereditary angioedema, along with the other liver-focused programs. These include hemophilia A and B, Hyperoxaluria Type 1, and alpha-1 antutrypsin deficiency.

    NTLA stock focuses on the programs exclusively and also partners up with potential strategically beneficial institutes, clinics and biotech firms for developing, discovering, designing, and clinically testing treatments and therapeutics. This includes companies like Novartis Institutes for BioMedical Therapeutics, Inc. with which it focuses on for the development and engineering of hematopoietic stem cells in order to treat sickle cell diseases. The partnership is based on collaboration and licensing agreement. The company also focuses on the co-development of potential treatments for hemophilia A and B, and Ospedale San Raffaelewith Regeneron Pharmaceuticals Inc. Intellia Therapeutics was previously known as AZRN till July 2014 and NTLA stock was incorporated in 2014  as well. The headquarter is based in Cambridge Massachusetts.

    Major advancement in the CRISPR genome editing done in collaboration with Regeneron Pharmaceuticals inc.

    The company has recently made a breakthrough in the Phase 1 Trial of the vivo CRISPR genome editing in humans by finding and observing data that it is the first of its kind to support safety and efficacy of the gene editing. The clinical data specifically showcases deep reduction in disease-causing protein after single infusion of NTLA-2001. The empirical result of the efficacy displayed an 87% reduction in serum TTR through a 0.3 mg/kg dose of NTLA 2001 which furthered to a 96% max reduction after 27 days.

    During these 28 days, there were no serious deviations from expected results or adverse events observed for the first six patients.  The company has now decided to add this data in The New England Journal of Medicine and also already presented the data in the 2021 Peripheral Nerve Society (PNS) on 26th June 2021, Saturday.

  • CEL-SCI Corp. (CVM) Stock Prices on the Rise Following Continued Development of Multikine

    CEL-SCI Corp. (CVM) Stock Prices on the Rise Following Continued Development of Multikine

    CEL-SCI Corp. (CVM) stock prices were up by 5.20% as of the market closing on June 25th, 2021, bringing the price per share up to USD$25.08 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 7.42%, bringing it up to USD$26.94.

    Bought Deal

    June 11th, 2021 saw the company announce its entering into an underwriting agreement with Kingswood Capital Market. As per the agreement, the underwriter made a purchase of 1.4 million shares of CVM’s common stock. Each share was priced at USD$22.62, with gross proceeds amounting to USD$31.7 million before the deduction of expenses related to the offering. The agreement also included a 30-day option for underwriters to purchase up to an addition 210,000 shares to cover over-allotments.

    MultikineTrial

    December 2020 saw the company’s Phase 3 head and neck cancer study complete database lock and enter the statistical analysis phase. Independent contractors have been hired to conduct the analysis process so as to ensure CVM stays blind to the study data. The company hopes to meet FDA safety and efficacy requirements, with the statistical analysis plan following the protocol states objectives. Furthermore, the company is keen to compile the clinical benefits the Multikine has the potential to provide patients that are newly diagnose, but not yet treated, for advanced primary squamous cell carcinoma of the head and neck.

    Multikine Production Facility

    With the commercial launch of Multikine looming closer, CVM has been allocating resources towards the expansion and upgrading of its proprietary cGMP manufacturing facility for Multikine. Construction began in 2020, with completion anticipated for the next several months. Upon completion, the company plans to double the facility’s capacity to accommodate two shifts for maximum production of Multikine.

    Financial Reports

    The six month period ended March 2021 saw the company report an operating loss of USD$17.3 million, up from the USD$13.6 million reported for the six month period ended March 31st, 2020. Operating loss for the quarter ended March 31st, 2021 was USD$8.5 million, up from the USD$6.7 million reported for the same time period of the prior year. The six and three-month periods ended March 31st, 2021, respectively reported USD$6.9 million and USD$3.3 million in capitalized costs.

    Future Outlook for CVM

    Armed with the nearing commercialization of Multikine, CVM is poised to continue its trajectory of success by allocating resources towards Multikine’s proliferation in the U.S and global markets. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • What Is The Reason Behind CSGP Stock Fluctuating Premarket?

    What Is The Reason Behind CSGP Stock Fluctuating Premarket?

    At last check, shares of CoStar Group Inc. (CSGP) were down -89.84% to $89.71 in premarket trading. CoStar stock gained 0.50% Friday, closing at $88.26. CSGP stock volume rose to 9.02 million shares, compared to an average daily volume of 0.22 million shares over the past 50 days. A share of CSGP has increased by 24.98% over the last 12 months, and it has moved up by 0.42% over the past week.

    It has gained 8.11% over the past three months and shed -2.77% over the past six months. In addition, CSGP’s current market value is $3.47 billion and it has 39.16 million shares outstanding. Price of CSGP stock is fluctuating before today’s stock split.

    CSGP will split its stock in what manner?

    CoStar is an online marketplace and an information company focusing on commercial real estate. CSGP was founded in 1987 and conducts extensive research on commercial real estate in order to produce and maintain the largest and most comprehensive database available.

    Through CSGP’s online services, clients can analyze market conditions, and gain unmatched insight about commercial property values, current availability, and market conditions. In the global hospitality industry, CSGP provides benchmarking data, analytics, and market insights.

    A ten-to-one split of the common stock of CSGP was approved and declared by CoStar’s Board of Directors this month.

    • As a result of both the split and the dividend, employees and investors will have a greater sense of ownership of the CSGP stock.
    • For stock dividends, the record date has been set for June 17, 2021.
    • For each share then held by a stockholder of record on the record date, CSGP will issue nine additional shares of common stock.
    • After the close of trading on June 25, 2021, dividend shares will be distributed and will begin trading on June 28, 2021 in accordance with the stock split.

    The acquisition strategy of CSGP:

    CoStar completed the purchase of Homes.com last month.

    • CSGP previously announced the $156 million purchase on April 14, 2021.
    • A final consent order was issued late last month by the Federal Trade Commission (FTC) to close that transaction.
    • The CSGP intends to discontinue Homes.com products and practices that do not conform to the principle that leads generated by an agent’s listings belong to that agent.

    CSGP Strategy for new acquisition:

    As one of the industry’s leading online marketplaces, CoStar (CSGP) has been growing website traffic with sites like Apartments.com, LoopNet, and others for years. Over one billion visits were made to CSGP’s marketplaces last year.

    CSGP plans to grow Homes.com in a similar manner by providing accurate, real-time information straight from the local MLS backed up with the best multimedia and photography, all on a website that empowers people to work directly with real estate agents.

  • Do You Know Why Birchcliff (BIREF) Stock Jumped 9% Last Session?

    Do You Know Why Birchcliff (BIREF) Stock Jumped 9% Last Session?

    Birchcliff Energy Ltd (OTCPink: BIREF) finished the previous session up 9.12% to $3.9500. Compared with its average weekly volume of 733.20K, the Birchcliff stock volume was 3.29M. After the release of its ESG report, BIREF stock took off.

    What did BIREF’s ESG report say?

    Birchcliff is an intermediate oil and natural gas company based in Calgary, Alberta, with operations concentrated in the Peace River Arch of Alberta.

    Birchcliff this month released its ESG Report for 2020. For the year ended December 31, 2020, the report outlines BIREF’s environmental, social, and governance (“ESG”) activities. BIREF is committed to ensuring it remains a leader in all aspects of environmental, social, and governance performance.

    The BIREF continued to expand its focus on improving emissions performance and protecting the environment, cultivating and strengthening relationships with the local communities, and advancing a deeply embedded culture of health and safety excellence in the year 2020.

    Low-intensity emitter of greenhouse gases

    With 0.00129 tonnes of carbon dioxide equivalent per barrel of oil equivalent, BIREF has continued to be one of the lowest greenhouse gas (GHG) emitters in Canada’s oil and natural gas industry, a reduction of approximately 44% when compared to its peers.

    BIREF continues to take steps to reduce its carbon footprint across all areas of its operations, including through its Methane Reduction and Retrofit Compliance Plan, its Fugitive Emissions Management Program, its carbon sequestration activities, and its focus on innovation to streamline its drilling and completion processes.

    Since BIREF has one of the lowest total GHG emissions among its peers and is devoted to its ongoing efforts to further reduce its emission intensity, it is labeled as a Low Emission Intensity Producer (LEIP).

    Best Health, Safety, and Environment Management

    BIREF awarded by Canadian Occupational Safety magazine in 2020 in the categories “Best Health, Safety, and Environment Management Program” followed by “Canada’s Safest Oil and Gas Employer” as well as “The WSIB award for Canada’s Best Health and Safety Culture.”.

    Innovative Approach

    BIREF is a partner in the Natural Gas Innovation Fund (“NGIF”) with two subsidiaries: NGIF Industry Grants and NGIF Cleantech Ventures Equity Fund. By investing in and supporting early-stage clean technology companies that develop technologies for reducing emissions, increasing energy efficiency, and utilizing natural gas for environmental goals in Canada, these subsidiary companies help the government achieve long-term environmental goals.

    Aboriginal Relations

    Briechcliff (BIREF)’s successful relationships with the Indigenous communities in its service areas are built on trust. With years of collaborative and constructive work, BIREF has invested significant time and resources in building strong, longlasting partnerships with Indigenous groups.

  • Greenland Tech Holding Corp. (GTEC) Stock Falls Following New of Upcoming Public Offering

    Greenland Tech Holding Corp. (GTEC) stock prices were down by a marginal 2.58% as of the market closing on June 25th, 2021, bringing the price per share down to USD$9.07 at the end of the trading day. Subsequent pre-market fluctuations saw the stock fall by a significant 15.21%, bringing it down to USD$7.69.

    Strategic Partnership

    The company announced on June 21st, 2021 that it had entered into a major strategic partnership with Shandong Zhongcha Heavy Industry Machinery Co. The companies plan to collaboratively launch a lithium battery forklift, which will make use of GTEC’s innovative integrated drivetrain system that will be available for sale in the U.S by July 2021. To further drive revenue generation and consolidate their market leadership, GTEC plans to combine R&D resources to develop the new lithium powered forklifts.

    Launch of EV Pre-Booking

    June 15th, 2021 saw the company announce the launch of its online EV pre-booking service for the GEL-1800 1.8 ton Electric Loader, as well as the GEX-8000 Electric Excavator. Deliveries are forecasted for August 2021, ahead of schedule. The company website offers more information, as well as a service to pre-book a vehicle with a USD$250 refundable deposit.

    Success of Pre-Booking

    As the company expands its product portfolio and raises brand awareness, the highly promising initial interest has the momentum to carry the company through to a successful launch. In the absence of alternative industrial electric vehicles on the market, the upcoming launches are expected to be highly disruptive. Pre-bookings afford customers the chance to integrate products into their existing budget cycles as fiscal forecasts, while offering GTEC increases visibility and ramp production.

    Product Portfolio Expansion

    GTEC’s GEL-1800 Electric Loader has a maximum loading capacity of nearly 1800 kg and comes equipped with a massive 144 kWh battery. The vehicle is designed to be used in a variety of applications, including construction, mining, farming, and industrial. The GEX-Electric Excavator is an 8 ton electric excavator that has a minimal pollution footprint as compared to traditional internal combustion engines while having the power to get the most challenging jobs done. The GEX-8000’s absence of carbon emissions reflect a safer option for the workplace, operators, and the local community.

    Future Outlook for GTEC

    Armed with the upcoming commercialization and proliferation of its new products in a prime market, GTEC is poised to continue its trajectory of success. The company is keen to usher in further growth with its continued efforts to maximize market penetration. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • SenesTech, Inc. (SNES) Stock Surge Following Continued Proliferation of ContraPest

    SenesTech, Inc. (SNES) stock prices were up by 4.40% as of the market closing on June 25th, 2021, bringing the price per share up to USD$1.66 at the end of the trading day. Subsequent pre-market fluctuations saw the stock surge by another 7.23%, bringing it up to USD$1.78.

    New Brand Campaign

    May 2021 saw the company launch a new brand campaign, The Pest Control Difference, with its proprietary ContraPest at the forefront. The rebranding of the company’s image comes in line with its transition from a science-based research company to a solutions based commercial company. SNES is keen to highlight its environmental responsibility as it provides an innovative and effective tool for pest control management in the 21st century.

    ContraPest

    March 2021 saw the company complete model agricultural deployments of ContraPest, which had a proven track record of successfully reducing rodent populations and, consequently, improving operating economies in poultry settings. A measurable reduction in rodent populations was reported within six months of deployment at both an eff production farm and a pullet house. Within a year of adding ContraPest, the egg farm reported a 95% decline in rodent activity.

    ContraPest Success

    The company also reported a long-term deployment that was completed in March 2021, with the East Coast urban setting reporting highly promising results. Data from the twelfth month showed a 94% reduction in rat activity at Site A, as well as a 98% reduction in juvenile rat photos since the start of monitoring. Site B reported a 99% reduction in rodent activity, with a 100% reduction in juvenile rat photos during the same period.

    Scope of ContraPest

    As of January 1st, 2021, California’s AB1788 bill was signed by the Governor and became law. The California Ecosystems Protection Act from 2020 will accordingly result in the prohibition of the four main SGAR’s used to treat rodent pest control problems. With ContraPest being a viable alternative, this development has seen a market space open up for SNES that could amount to a potential USD$100 million every year.

    Solid Financials

    Revenue for the first quarter of the fiscal year 2021 was reported at USD$88,000, up from the USD$37,000 reported in the same quarter of the prior year. The 138% year-over-year increase is not inclusive of more than USD$20,000 of backlog, with late orders fulfilled in April 2021 being included in the second quarter of 2021’s numbers. As of the end of Q1 2021, SNES reported a solid liquidity position of USD$15.2 million.

    Future Outlook for SNES

    Armed with a solid liquidity position, SNES is poised to capitalize on the proliferation of its ContraPest technology. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • How Has The Trevena (TRVN) Stock Declined 13% In Extended Trades?

    How Has The Trevena (TRVN) Stock Declined 13% In Extended Trades?

    In after-hours trading, shares of Trevena Inc. (TRVN) were down -12.76% on Friday. The stock closed the previous trading session up 2.62% or $0.05 at $1.96. The stock fluctuated between $1.93 and $2.00 throughout the day. A total of 22.49 million shares were exchanged, more than TRVN’s 50-day volume of 3.41 million as well as its year-to-date volume of 3.46 million.

    The TRVN stock has lost 13.95 percent in the past 12 months, and in the last week the stock has gained 2.62%. A total of -20.33 % has been lost by TRVN stock over the last six months, and 7.10 % has been gained over the last three months. The TRVN stock price is down by 8.41% this year. In response to the reinstatement of patient recruitment for one of its studies, TRVN stock rose.

    In what study did TRVN take part?

    Trevena specializes in developing and commercializing treatments for patients with disorders of the central nervous system. A TRVN product, OLINVYK (oliceridine) injection, is approved in the United States for the treatment of adults who have acute pain severe enough to require intravenous opioid analgesic therapy and for whom alternative treatments are ineffective.

    TRRVN’s novel pipeline includes four investigational drug candidates that are the result of Nobel Prize-winning research. TRV027 is used to treat acute respiratory distress syndrome, abnormal blood clotting, and COVID-19-related symptoms; TRV734 treats opioid use disorder; TRV250 treats migraines and TRV045 treats epilepsy.

    Trevena announced recently that NIDA has reopened enrollment for its TRV734 prospective patient study, which tests the new mu opioid receptor selective agonist.

    • As part of TRVN’s ongoing collaboration with NIDA, TRV734 is being evaluated as potential maintenance therapy for opioid use disorder (OUD).
    • As a result of the global COVID-19 pandemic in March 2020, TRVN has paused its study.
    • In spite of COVID-19, opioid use disorder (OUD) is still a public health emergency.
    • TRVN believes it is important to continue developing effective treatments for patients suffering from opioid addiction.
    • By resuming their TRV734 study, NIDA emphasizes the unmet need for treatments for OUD, as TRV734 may be an effective treatment option with improved tolerability.
    • NIH and TRVN will join forces to explore a number of its pipeline assets as part of this collaboration.
    • This study aims to enroll approximately 50 opioid-dependent people undergoing stable methadone maintenance therapy in a double-blind, placebo- and positive-controlled study.
    • Using the Clinical Opioid Withdrawal Scale, this study will also evaluate whether TRVN’s TRV734 suppresses withdrawal symptoms.

    How the TRVN candidate will be evaluated?

    TRV734 will be the third Trevena (TRVN) investigational drug product being studied by NIDA. According to the Subjective Opioid Withdrawal Scale, the primary outcome is a reduction in withdrawal symptoms through TRVN drug. Additionally, secondary outcomes will include an assessment of safety, tolerability, and measure of changes in neurocognitive function of TRVN candidate.